美国新发2型糖尿病患者在强化治疗后2年心血管危险因素负担
基于美国Centricity电子病历中276,884例新发2型糖尿病并强化二甲双胍治疗的患者,评估强化治疗后2年血糖和心血管危险因素的持续控制情况。结果显示,尽管多数患者接受降压和调脂治疗,仍有超过三分之一患者HbA1c、血脂和收缩压未达标,超过半数患者同时有两个心血管危险因素未控制。
要点
- 强化治疗后2年,63%患者HbA1c+LDL未同时达标,57%患者HbA1c+SBP未同时达标。
- 持续HbA1c未控制比例从2005年31%升至2014年41%。
- 接受调脂治疗者中41% LDL持续偏高,接受降压治疗者中29% SBP持续未控制。
核心结论
- 在接受多种风险因素控制治疗的患者中,超过三分之一血糖、血脂和收缩压未控制,超过半数有两个心血管危险因素同时未控制。
研究设计与样本
- 从美国Centricity电子病历中选取276,884例新发2型糖尿病并强化二甲双胍治疗的患者,纵向评估强化治疗后2年的危险因素负担,平均随访3.7年。
主要发现
- 患者平均59岁,70%肥胖,22%有心血管疾病史。
- 强化治疗时,60%患者HbA1c未控制,30%收缩压未控制,50% LDL未控制,48%甘油三酯未控制。
- 81%患者接受降压治疗,69%接受调脂治疗。
- 持续HbA1c未控制比例从2005年31%增至2014年41%;调脂治疗者中41% LDL持续偏高、37%甘油三酯持续偏高;降压治疗者中29%收缩压持续未控制。
- 强化治疗后2年,63%患者HbA1c+LDL未同时控制,57% HbA1c+SBP未同时控制,55% LDL+SBP未同时控制,63% HbA1c+甘油三酯未同时控制。
关键数值与推荐
- 收缩压≥130/140 mmHg(根据有无心血管疾病史)定义为未控制。
- LDL≥70/100 mg/dL(根据有无心血管疾病史)定义为未控制。
- 甘油三酯≥150 mg/dL和HbA1c≥7.5%(58 mmol/mol)定义为未控制。
临床怎么用
- 对新发2型糖尿病强化治疗患者,应定期评估血糖、血压和血脂的综合达标情况。
- 即使患者已接受降压或调脂治疗,仍需关注持续未控制的风险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Individualized treatment of patients with diabetes requires detailed evaluation of risk factor dynamics at the population level. This study evaluated the persistent glycemic and cardiovascular (CV) risk factor burden over 2 years after treatment intensification (TI). RESEARCH DESIGN AND METHODS: From U.S. Centricity Electronic Medical Records, 276,884 patients with incident type 2 diabetes who intensified metformin were selected. Systolic blood pressure (SBP) ≥130/140 mmHg and LDL ≥70/100 mg/dL were defined as uncontrolled for those with/without a history of CV disease at TI. Triglycerides ≥150 mg/dL and HbA1c ≥7.5% (58 mmol/mol) were defined as uncontrolled. Longitudinal measures over 2 years after TI were used to define risk factor burden. RESULTS: With 3.7 years' mean follow-up, patients were 59 years; 70% were obese; 22% had a history of CV disease; 60, 30, 50, and 48% had uncontrolled HbA1c, SBP, LDL, and triglycerides, respectively, at TI; and 81% and 69% were receiving antihypertensive and lipid-modifying therapies, respectively. The proportion of patients with consistently uncontrolled HbA1c increased from 31% in 2005 to 41% in 2014. Among those on lipid-modifying drugs, 41% and 37% had consistently high LDL and triglycerides over 2 years, respectively. Being on antihypertensive therapies, 29% had consistently uncontrolled SBP. Among patients receiving cardioprotective therapies, 63% failed to achieve control in HbA1c + LDL, 57% in HbA1c + SBP, 55% in LDL + SBP, and 63% in HbA1c + triglycerides over 2 years after TI. CONCLUSIONS: Among patients on multiple therapies for risk factor control, more than one-third had uncontrolled HbA1c, lipid, and SBP levels, and more than one-half had two CV risk factors that were simultaneously uncontrolled after TI.
引用
- Montvida O, Cai X, Paul SK, et al. Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective Therapies. Diabetes Care. 2019. PMID: 30679305. doi:10.2337/dc18-1865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。